According to research published in the journal Molecular Medicine Reports, blocking the reactive oxygen species-producing NOX1 enzyme prevented fibrotic changes in the lungs of mice exposed to irradiation, suggesting that pulmonary fibrosis caused by chest radiotherapy might be prevented by the use of specific blockers of the enzyme NOX1.
Radiotherapy-induced Lung Fibrosis Might Be Prevented by Blocking NOX1
Pirfenidone (Esbriet) is an anti-inflammatory and anti-fibrotic drug that reduces inflammation and fibrosis simultaneously. Pirfenidone is an approved pharmacological agent for the treatment of idiopathic pulmonary fibrosis (IPF). In this video, shared by Demystifying Medicine, a youtube channel from McMaster…
Pulmonary fibrosis is a heart and lung condition that causes the thickening of the walls of the alveoli, scarring the alveoli and lung tissue. Because of this thickening and scarring, the amount of oxygen that can pass into the blood vessels is reduced causing PF patients to experience shortness…
Veracyte, Inc., presented new data indicating that its in-development genomic test, the Envisia classifier, has the potential to diagnosis idiopathic pulmonary fibrosis (IPF), distinguishing it from other interstitial lung diseases (ILD), and reduce the need for invasive diagnostic surgeries. The findings were presented by Dr. Giulia C. Kennedy, the company’s chief scientific officer,…
https://www.youtube.com/watch?v=OICp4hEHTMo Idiopathic pulmonary fibrosis is a severely debilitating condition that leaves patients struggling to breathe. IPF is the rare lung disease which claimed the lives of Hollywood actor, Marlon Brando, and international daredevil, Evel Knievel. Unfortunately, most patients who suffer from this deadly respiratory condition have never heard of it until…
1. Medication Currently, two medicines are approved by the U.S. Food and Drug Administration (FDA) for patients with idiopathic pulmonary fibrosis (IPF). Both Esbriet (pirfenidone) and Ofev (nintedanib) became available in 2014. Taken orally, Esbiret is an anti-inflammatory and an anti-fibrotic drug shown effective in reducing inflammation and fibrosis simultaneously.
Afferent Pharmaceuticals announced the results from the first cohort of a two-cohort Phase 2b study, revealing that the company’s AF-219, an orally available antagonist of the P2X3 receptors, significantly reduced cough frequency in patients with chronic cough, a commonly experienced symptom in people with idiopathic pulmonary fibrosis (IPF). P2X3 receptors are activated…
Breathing is the process that moves air in and out of the lungs, or oxygen through other respiratory organs. This is one of the most important things that our body does, that allow us to be alive. Pulmonary fibrosis patients have difficulties in breathing, which means that something in their bodies…
https://www.youtube.com/watch?v=JcZuUt8jXBI The average survival of patients with idiopathic pulmonary fibrosis (IPF) is between three and five years after diagnosis, and only 20% of them survive past this time. Like many others, Anita Hatfield struggled for three years with the disease and died last March from complications related to idiopathic pulmonary fibrosis.
New analyses, presented at the American Thoracic Society (ATS) 2016 Annual Conference, further support the efficacy and safety of nintedanib (Ofev) in treating idiopathic pulmonary fibrosis (IPF). Boehringer Ingelheim shared a host of data at the meeting, establishing nintedanib as an important player in IPF management, irrespective of disease severity. “IPF…
